Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Daily

Download Data

Milestone Pharmaceuticals Inc Share Price on June 03, 2024: USD 1.51

Milestone Pharmaceuticals Inc Share Price is USD 1.51 on June 03, 2024, a -60.88% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.

Milestone Pharmaceuticals Inc 52-week high Share Price is USD 4.00 on June 08, 2023, which is 164.90% above the current Share Price.
Milestone Pharmaceuticals Inc 52-week low Share Price is USD 1.40 on January 19, 2024, which is -7.28% below the current Share Price.
Milestone Pharmaceuticals Inc average Share Price for the last 52 weeks is USD 2.42.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends